{
    "clinical_study": {
        "@rank": "11609", 
        "arm_group": [
            {
                "arm_group_label": "Nitrite", 
                "arm_group_type": "Experimental", 
                "description": "Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure."
            }, 
            {
                "arm_group_label": "Saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Saline Placebo for Nitrite will be infused for 5 minutes during the cardiac catheterization procedure."
            }
        ], 
        "brief_summary": {
            "textblock": "Heart failure with preserved ejection fraction (HFpEF) is a major public health problem that\n      has no proven effective treatment.  This study will assess the effects of acute nitrite\n      administration on resting and exercise hemodynamics in patients with HFpEF referred to the\n      catheterization lab."
        }, 
        "brief_title": "Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Heart Disease", 
            "Heart Failure With Preserved Ejection Fraction", 
            "Exercise Intolerance", 
            "Pulmonary Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Heart Diseases", 
                "Heart Failure", 
                "Hypertension", 
                "Hypertension, Pulmonary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Scheduled to undergo a cardiac catheterization procedure.\n\n          -  Clinical symptoms of shortness of breath and fatigue\n\n          -  Normal left ventricular ejection fraction (\u226550%)\n\n          -  Elevated left ventricular filling pressures at cardiac catheterization (defined as\n             resting PCWP>15 mmHg and/or PCWP\u226525 mmHg during exercise)\n\n        Exclusion Criteria:\n\n          -  Systolic BP <120 mmHg\n\n          -  Prior nitrate therapy (within previous 2 weeks)\n\n          -  G6PD-deficiency\n\n          -  Other \"non-HFpEF\" specific causes of heart failure such as significant valvular\n             disease (>moderate left-sided regurgitation, >mild stenosis), severe pulmonary\n             disease, unstable coronary disease or coronary spasm, primary renal or hepatic\n             disease, constrictive pericarditis, or infiltrative, restrictive, or hypertrophic\n             cardiomyopathies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01932606", 
            "org_study_id": "13-004077"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nitrite", 
                "description": "Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.", 
                "intervention_name": "Nitrite", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Saline", 
                "description": "Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure.  Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).", 
                "intervention_name": "Saline Placebo for Nitrite", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "contact": {
                "last_name": "Eric Bruhn", 
                "phone": "507-255-7100"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction", 
        "overall_contact": {
            "email": "borlaug.barry@mayo.edu", 
            "last_name": "Barry A Borlaug, MD", 
            "phone": "50728442"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Barry Borlaug, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Exercise pulmonary capillary wedge pressure", 
            "safety_issue": "No", 
            "time_frame": "during repeat exercise run, approximately 30 minutes after study drug administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01932606"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Barry Borlaug", 
            "investigator_title": "M.D., Associate Professor of Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Barry Borlaug", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}